Studies have shown that active fund managers routinely underperform the S&P500 index*​

Stoke Therapeutics, Inc. (NASDAQ: STOK)

STOK Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
35.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
26.70%

STOK Stock Analysis

STOK PE Ratio:

STOK PEG Ratio: Not Available

STOK Forward EPS Growth (12 month): 0.00%

STOK PS Ratio: 57.2

STOK PSG Ratio: 0.9

STOK Forward Revenue Growth (12 month): 60.30%

STOK Articles

No data was found